UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 82

Sortiert nach

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

NPJ Parkinson's Disease, 2023-07, Vol.9 (1), p.114-114, Article 114

2023

Volltextzugriff (PDF)

Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

NPJ Parkinson's Disease, 2024-03, Vol.10 (1), p.60-60, Article 60

2024

Volltextzugriff (PDF)

NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

International journal of inflammation, 2022-02, Vol.2022, p.2337363-12

2022

Volltextzugriff (PDF)

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

The Journal of pharmacology and experimental therapeutics, 2007-08, Vol.322 (2), p.862

2007

Volltextzugriff (PDF)

NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease

Brain (London, England : 1878), 2021-12, Vol.144 (12), p.3692-3709

2021

Volltextzugriff (PDF)

Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists

Bioorganic & medicinal chemistry letters, 2021-05, Vol.40, p.127861-127861, Article 127861

2021

Volltextzugriff (PDF)

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease

Behavioural pharmacology, 2011-10, Vol.22 (7), p.681

2011

Volltextzugriff (PDF)

Pharmacology of N-desmethylclozapine

Pharmacology & therapeutics (Oxford), 2007-08, Vol.115 (2), p.223-231

2007

Volltextzugriff (PDF)

Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease

Behavioural pharmacology, 2012-08, Vol.23 (4), p.426

2012

Volltextzugriff (PDF)

The 5-HT3 Subtype of Serotonin Receptor Contributes to Nociceptive Processing via a Novel Subset of Myelinated and Unmyelinated Nociceptors

The Journal of neuroscience, 2002-02, Vol.22 (3), p.1010-1019

2002

Volltextzugriff (PDF)

AC260584 (4-[3-(4-butylpiperidin-1 -yl )-propyl]-7-fluoro-4H-benzo[1,4] oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus

European journal of pharmacology, 2007-10, Vol.572 (2-3), p.129-137

2007

Volltextzugriff (PDF)

AC-186, a Selective Nonsteroidal Estrogen Receptor β Agonist, Shows Gender Specific Neuroprotection in a Parkinson’s Disease Rat Model

ACS chemical neuroscience, 2013-09, Vol.4 (9), p.1249-1255

2013

Volltextzugriff (PDF)

AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus

European journal of pharmacology, 2007-10, Vol.572 (2-3), p.129

2007

Volltextzugriff (PDF)

Discovery of potential antipsychotic agents possessing pro-cognitive properties

Naunyn-Schmiedeberg's archives of pharmacology, 2012-03, Vol.385 (3), p.313-323

2012

Volltextzugriff (PDF)

Allosteric modulation of [ 3H]gabapentin binding by ruthenium red

Neuropharmacology, 2000-06, Vol.39 (7), p.1267-1273

2000

Volltextzugriff (PDF)

Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat

Psychopharmacologia, 2003, Vol.165 (2), p.128-135

2003

Volltextzugriff (PDF)

Alzheimer's disease psychosis: Potential therapeutic benefit of pimavanserin, a 5-HT2A inverse agonist

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S548-S548

2010

Volltextzugriff (PDF)

P1-013: Antipsychotic-like activity of pimavanserin, A 5-ht2a inverse agonist, in putative animal models of Alzheimer's disease psychosis

Alzheimer's & dementia, 2008-07, Vol.4 (4), p.T209-T209

2008

Volltextzugriff (PDF)

RS‐127445: a selective, high affinity, orally bioavailable 5‐HT2B receptor antagonist

British journal of pharmacology, 1999-07, Vol.127 (5), p.1075-1082

1999

Volltextzugriff (PDF)

Structure based design and synthesis of novel Toll-like Receptor 2

Bioorganic & medicinal chemistry letters, 2021-05, Vol.40

2021

Volltextzugriff (PDF)

Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands

BMC pharmacology, 2009-12, Vol.9 (1), p.14-14, Article 14

2009

Volltextzugriff (PDF)

Catecholamine modulatory effects of nepicastat (RS‐25560‐197), a novel, potent and selective inhibitor of dopamine‐β‐hydroxylase

British journal of pharmacology, 1997-08, Vol.121 (8), p.1803-1809

1997

Volltextzugriff (PDF)

AC-260584, an orally bioavailable M 1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

Neuropharmacology, 2010-02, Vol.58 (2), p.365-373

2010

Volltextzugriff (PDF)

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

Neuropharmacology, 2010-02, Vol.58 (2), p.365-373

2010

Volltextzugriff (PDF)

2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists

Journal of medicinal chemistry, 1993-09, Vol.36 (18), p.2645-2657

1993

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(82)

Sprache

Englisch
(82)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(39)
Animals
(38)
Biological And Medical Sciences
(27)
Rats
(27)
Neurosciences & Neurology
(26)
Neurosciences
(25)
Male
(23)
Medical Sciences
(21)
Pharmacology & Pharmacy
(20)
Mice
(13)
Neurology
(12)
Rats, Inbred Strains
(11)
Humans
(10)
Pharmacology. Drug Treatments
(10)
Rats, Sprague-Dawley
(10)
Neuropharmacology
(9)
Phencyclidine - Analogs & Derivatives
(9)
Radioligand Assay
(9)
Receptors, Serotonin - Metabolism
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease

NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease

Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease

Pharmacology of N-desmethylclozapine

Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease

The 5-HT3 Subtype of Serotonin Receptor Contributes to Nociceptive Processing via a Novel Subset of Myelinated and Unmyelinated Nociceptors

AC260584 (4-[3-(4-butylpiperidin-1 -yl )-propyl]-7-fluoro-4H-benzo[1,4] oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus

AC-186, a Selective Nonsteroidal Estrogen Receptor β Agonist, Shows Gender Specific Neuroprotection in a Parkinson’s Disease Rat Model

AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus

Discovery of potential antipsychotic agents possessing pro-cognitive properties

Allosteric modulation of [ 3H]gabapentin binding by ruthenium red

Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat

Alzheimer's disease psychosis: Potential therapeutic benefit of pimavanserin, a 5-HT2A inverse agonist

P1-013: Antipsychotic-like activity of pimavanserin, A 5-ht2a inverse agonist, in putative animal models of Alzheimer's disease psychosis

RS‐127445: a selective, high affinity, orally bioavailable 5‐HT2B receptor antagonist

Structure based design and synthesis of novel Toll-like Receptor 2

Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands

Catecholamine modulatory effects of nepicastat (RS‐25560‐197), a novel, potent and selective inhibitor of dopamine‐β‐hydroxylase

AC-260584, an orally bioavailable M 1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists

Suchergebnisse filtern